Gregory Allen, DO
Internal Medicine · Cranston, RINPI 1043217250
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,570 of the $37,926 with a category attached, or 75.3%. AbbVie accounts for 80.3% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2020 at $15,314 and has fallen 84.4% since, to $2,388 in 2025. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 443 payments — averaging $85.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Pfizer$2K
- Novo Nordisk$1K
- Boehringer Ingelheim$723
- Amgen$529
- Johnson & Johnson$355
- plus $2K from 25 others
Across 268 payments — averaging $45,235 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Quidel Corporation$7.3M
- Ortho-clinical Diagnostics, Inc.$3M
- BD$1.8M
- Akebia Therapeutics Inc$113K
- Bayer$9K
- Amgen$8K
- plus $11K from 4 others
What the payments were for
- Consulting fees$1,0653%
- Speaking & faculty fees$28,57075%
- Travel & lodging$9733%
- Food & beverage$7,24319%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 146 | $30,448 |
| Pfizer | 65 | $2,110 |
| Novo Nordisk | 12 | $1,333 |
| Boehringer Ingelheim | 34 | $723 |
| Amgen | 23 | $529 |
| Johnson & Johnson | 19 | $355 |
| AstraZeneca | 21 | $348 |
| GSK | 19 | $329 |
| Lilly USA, LLC | 17 | $287 |
| Abbott | 10 | $266 |
| E.r. Squibb & Sons, L.L.C. | 11 | $205 |
| Sanofi-aventis U.S. LLC | 8 | $136 |
| Merck | 21 | $128 |
| Inspire Medical Systems, Inc. | 6 | $116 |
| Exact Sciences | 5 | $113 |
| Sumitomo Pharma America, Inc. | 3 | $67 |
| Verona Pharma, Inc. | 2 | $61 |
| Bayer | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| Boston Scientific | 1 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Biogen | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,926 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $60,516 |
| OzempicSemaglutide | 49 | $51,872 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $46,083 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 36 | $43,878 |
| JardianceEmpagliflozin | 47 | $40,974 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $27,755 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $21,143 |
| XareltoRivaroxaban | 18 | $17,187 |
| EntrestoSacubitril/Valsartan | 23 | $16,684 |
| FarxigaDapagliflozin Propanediol | 17 | $16,676 |
| LinzessLinaclotide | 18 | $13,156 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $12,621 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,686 |
| Diclofenac Sodium | 16 | $10,439 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Jentadueto Xr | $723 | $65,28690 claims |
| PfizerEliquis | $2,110 | $60,51691 claims |
| Novo NordiskOzempic | $1,333 | $51,87249 claims |
| MerckJanumet Xr, Janumet | $128 | $49,25753 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $329 | $44,45070 claims |
| AstraZenecaFarxiga, Symbicort | $348 | $20,16231 claims |
| Johnson & JohnsonXarelto | $355 | $17,18718 claims |
| AbbVieLinzess, Synthroid | $30,448 | $15,63742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Cranston
- Joseph CampbellCranston$13K
- Dennis BotelhoCranston$12K
- Stephen BeaupreCranston$8K
- Usha PanneerselvamCranston$7K
- Olga TverskayaCranston$6K
- Leah AdamsCranston$4K
- William BeliveauJohnson$951K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Frank D'alessandroLincoln$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.